These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20859436)

  • 101. Institutional Priority-Setting for Novel Drugs and Therapeutics: A Qualitative Systematic Review.
    Wang DE; Hassanein M; Razvi Y; Shaul RZ; Denburg A
    Int J Health Policy Manag; 2024; 13():7494. PubMed ID: 38618836
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Priority-setting for hospital funding of high-cost innovative drugs and therapeutics: A qualitative institutional case study.
    Razvi Y; Horwitz SL; Cressman C; Wang DE; Shaul RZ; Denburg A
    PLoS One; 2024; 19(3):e0300519. PubMed ID: 38498497
    [TBL] [Abstract][Full Text] [Related]  

  • 103. The reimbursement for expensive medicines: stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy.
    Scheijmans FEV; Zomers ML; Fadaei S; Onrust MR; van der Graaf R; Delden JJMV; van der Pol WL; van Thiel GJMW
    BMC Health Serv Res; 2022 Nov; 22(1):1320. PubMed ID: 36333803
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Organizational aspect in healthcare decision-making: a literature review.
    Dubromel A; Duvinage-Vonesch MA; Geffroy L; Dussart C
    J Mark Access Health Policy; 2020 Aug; 8(1):1810905. PubMed ID: 32944200
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Impact of a novel prioritization framework on clinician-led oncology drug submissions.
    Keech J; Beca J; Eisen A; Kennedy E; Kim J; Kouroukis CT; Darling G; Ferguson SE; Finelli A; Petrella TM; Perry JR; Chan K; Gavura S
    Curr Oncol; 2019 Apr; 26(2):e155-e161. PubMed ID: 31043821
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Sustainability in Health care by Allocating Resources Effectively (SHARE) 10: operationalising disinvestment in a conceptual framework for resource allocation.
    Harris C; Green S; Elshaug AG
    BMC Health Serv Res; 2017 Sep; 17(1):632. PubMed ID: 28886740
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Sustainability in Health care by Allocating Resources Effectively (SHARE) 6: investigating methods to identify, prioritise, implement and evaluate disinvestment projects in a local healthcare setting.
    Harris C; Allen K; Brooke V; Dyer T; Waller C; King R; Ramsey W; Mortimer D
    BMC Health Serv Res; 2017 May; 17(1):370. PubMed ID: 28545430
    [TBL] [Abstract][Full Text] [Related]  

  • 108. From efficacy to equity: Literature review of decision criteria for resource allocation and healthcare decisionmaking.
    Guindo LA; Wagner M; Baltussen R; Rindress D; van Til J; Kind P; Goetghebeur MM
    Cost Eff Resour Alloc; 2012 Jul; 10(1):9. PubMed ID: 22808944
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa.
    Miot J; Wagner M; Khoury H; Rindress D; Goetghebeur MM
    Cost Eff Resour Alloc; 2012 Feb; 10(1):2. PubMed ID: 22376143
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Can quality-adjusted life year avoidance help in oncology drug reimbursement decisions?
    Calfee JE
    J Oncol Pract; 2008 Jan; 4(1):8. PubMed ID: 20859437
    [No Abstract]   [Full Text] [Related]  

  • 111. Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients.
    Goetghebeur MM; Wagner M; Khoury H; Rindress D; Grégoire JP; Deal C
    Cost Eff Resour Alloc; 2010 Apr; 8():4. PubMed ID: 20377888
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Evidence and Value: Impact on DEcisionMaking--the EVIDEM framework and potential applications.
    Goetghebeur MM; Wagner M; Khoury H; Levitt RJ; Erickson LJ; Rindress D
    BMC Health Serv Res; 2008 Dec; 8():270. PubMed ID: 19102752
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Priority setting and cardiac surgery: a qualitative case study.
    Walton NA; Martin DK; Peter EH; Pringle DM; Singer PA
    Health Policy; 2007 Mar; 80(3):444-58. PubMed ID: 16757057
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 115. 6-STEPPPs: A Modular Tool to Facilitate Clinician Participation in Fair Decisions for Funding New Cancer Drugs.
    Browman GP; Manns B; Hagen N; Chambers CR; Simon A; Sinclair S
    J Oncol Pract; 2008 Jan; 4(1):2-7. PubMed ID: 20859436
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs.
    Costa S; Bentley C; Regier DA; McTaggart-Cowan H; Mitton C; Burgess MM; Peacock SJ
    BMC Public Health; 2019 Jul; 19(1):977. PubMed ID: 31331312
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Accounting for reasonableness: Exploring the personal internal framework affecting decisions about cancer drug funding.
    Sinclair S; Hagen NA; Chambers C; Manns B; Simon A; Browman GP
    Health Policy; 2008 May; 86(2-3):381-90. PubMed ID: 18243395
    [TBL] [Abstract][Full Text] [Related]  

  • 118.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 119.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 120.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.